Recordati Launches Fortacin OTC In Germany Following EU-Wide Switch

Men in Germany can now purchase premature ejaculation treatment Fortacin without a prescription as a result of the EU-wide switch of the drug earlier this year.

Close-up of colored map of Europe zoomed in on Germany
• Source: Shutterstock

Recordati has launched its premature ejaculation treatment Fortacin as an OTC product in Germany following an EU-wide switch through the European Medicines Agency’s centralized procedure.

While the European Commission in August approved the reclassification of Fortacin all 27 EU member states, plus in the European...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rx-to-OTC Switch

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By 

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By 

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Viatris Switches Innovative Dual Action Nasal Spray In The UK

 
• By 

Now available without a prescription, Dymista Control is the first OTC combination treatment for consumers who are struggling to control their seasonal allergic rhinitis with a corticosteroid or antihistamine nasal spray, according to the firm.

Haleon Study: Self-Care Policies Could Save Finland €60m Per Year

 
• By 

Creating a working group to drive Rx-to-OTC switch is one of the ways in which Finland could expand self-care and save €60m per year for the country's health system, suggests a recently published report commissioned by Haleon.

More from Health

Softness In US And China Holds Back Bayer Consumer Health

 
• By 

Like its peers, Bayer Consumer Health has struggled in the challenging US market in the first half of 2025 and says it doesn't expect conditions to change this year.

Repeat Buyers Passing 50% Key For Opill Sales Leading Perrigo’s Women’s Health Growth

 

“We continue to grow the brand. It was slower than initially anticipated or forecasted in basis, but I'm pleased with how it's developing,” says CEO Patrick Lockwood-Taylor of Opill performance.

Recordati Benefits From Cough & Cold Rebound

 
• By 

OTC sales grew at Italy's Recordati in the first half of 2025, with an improving cough and cold picture contributing to the rise.